For its investors, OncoMed Pharmaceuticals Inc. had bad news and then more bad news on April 10 and they reacted in the expected way on learning that pancreatic cancer candidate demcizumab failed a Phase II trial and that Bayer AG had declined its options under a 2010 deal for a pair of Phase II-ready Wnt pathway inhibitors.
The Redwood City, Calif.-based biotech's stock price dropped steeply after the news, although recovering a bit by the end of the day's trading
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?